Vistagen Therapeutics, Inc.: 5%+ holders

As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Vistagen Therapeutics, Inc. The largest reported stake is Chen Yu's, at 9.99%. 17 filings are on record since August 14, 2025 (Schedule 13G/A, May 15, 2026).

StemPoint Capital LP also filed stake reports on 4 other companies ↓

Sell to companies like Vistagen Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Latest 2026-08-14 · Holder: Commodore Capital LP · Percent: 9.9% · Shares: 4,244,590 · SCHEDULE 13G/A
• Filing 2026-08-14 · Reporting person: TCG Crossover GP I, LLC · Sole voting: 0 · Shared voting: 740,101 · Sole dispositive: 0 · Shared dispositive: 740,101 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Orbimed Advisors LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-14
• Filed 2026-05-15 · Holder: Chen Yu · Percent: 9.99% · SCHEDULE 13G/A
• Filed 2026-02-17 · Holder: Orbimed Capital LLC · Percent: 4.2% · SCHEDULE 13G/A

Vistagen Therapeutics, Inc. has 17 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 1 filing or notice, latest 2026-10-30 (layoff filings and notices).

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Vistagen Therapeutics, Inc. and the warning signs.

See Vistagen Therapeutics, Inc.'s free Snapshot Watch Vistagen Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Vistagen Therapeutics, Inc. and the records around it.

Vistagen Therapeutics, Inc. elsewhere on the record

• Leadership changes Jul 2026
• Who owns it

Companies that share a holder

• StemPoint Capital LP also filed stake reports on 4 other companies: Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026)
• TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Entrada Therapeutics, Inc. (Aug 2026), Savara Inc. (Feb 2026)
• Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)

Want the whole picture on Vistagen Therapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Vistagen Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Vistagen Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   21 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Vistagen Therapeutics, Inc. by CUSIP 92840H400 and gives its principal executive office as 343 Allerton Avenue, South San Francisco, CA 94080 (SCHEDULE 13G/A, 2026-08-14).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Vistagen Therapeutics, Inc.

Who owns Vistagen Therapeutics, Inc.?

On this page, 3 holders' latest ownership filings report 5% or more of Vistagen Therapeutics, Inc.: Chen Yu (9.99%, Schedule 13G/A, filed 2026-05-15), Commodore Capital LP (9.9%, Schedule 13G/A, filed 2026-08-14) and Chen Yu (6.7%, Schedule 13G/A, filed 2026-08-14).

Who are the largest shareholders of Vistagen Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of Vistagen Therapeutics, Inc. on this page are Chen Yu (9.99%), Commodore Capital LP (9.9%) and Chen Yu (6.7%).

When did Chen Yu buy into Vistagen Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Chen Yu on this page is the Schedule 13G/A, filed 2026-05-15, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Vistagen Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Vistagen Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Vistagen Therapeutics, Inc. is mentioned again
• Find former Vistagen Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes